Zobrazeno 1 - 10
of 186
pro vyhledávání: '"Marek Trněný"'
Autor:
Lale Kostakoglu, Maurizio Martelli, Laurie H. Sehn, Andrew Davies, Marek Trněný, Michael Herold, Umberto Vitolo, Wolfgang Hiddemann, Judith Trotman, Andrea Knapp, Federico Mattiello, Tina G. Nielsen, Deniz Sahin, Gila Sellam, Carol Ward, Anas Younes
Publikováno v:
eJHaem, Vol 4, Iss 4, Pp 1042-1051 (2023)
Abstract The Lugano 2014 criteria are the standard for response assessment in lymphoma. We compared the prognostic performance of Lugano 2014 and the more recently developed response evaluation criteria in lymphoma (RECIL 2017), which relies primaril
Externí odkaz:
https://doaj.org/article/8636eb2d27c84d4d9d7e4852dff05f6a
Autor:
Marek Trněný, Abraham Avigdor, Matthew S. McKinney, Shankara Paneesha, Björn E. Wahlin, John S. Hrom, David Cunningham, Nicholas Morley, Miguel Canales, Mariana Bastos-Oreiro, David Belada, Liliana Devizzi, Fred Zheng, Douglas J. DeMarini, Wei Jiang, Ping Jiang, Ryan C. Lynch
Publikováno v:
EClinicalMedicine, Vol 63, Iss , Pp 102130- (2023)
Summary: Background: Parsaclisib, a potent and highly selective PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell malignancies. This phase 2 study (CITADEL-203; NCT03126019, EudraCT 2017-001624-22) asse
Externí odkaz:
https://doaj.org/article/c66821b07c654aec8c095879560486da
Autor:
Pier Luigi Zinzani, Marek Trněný, Vincent Ribrag, Vittorio Ruggero Zilioli, Jan Walewski, Jacob Haaber Christensen, Vincent Delwail, Guillermo Rodriguez, Parameswaran Venugopal, Morton Coleman, Caroline Dartigeas, Caterina Patti, Fabrizio Pane, Wojciech Jurczak, Michal Taszner, Shankara Paneesha, Fred Zheng, Douglas J. DeMarini, Wei Jiang, Aidan Gilmartin, Amitkumar Mehta
Publikováno v:
EClinicalMedicine, Vol 62, Iss , Pp 102131- (2023)
Summary: Background: Parsaclisib is a potent and highly selective PI3Kδ inhibitor that has shown clinical benefit in patients with relapsed/refractory (R/R) B-cell malignancies. In this phase 2 study (CITADEL-205; NCT03235544, EudraCT 2017-003148-19
Externí odkaz:
https://doaj.org/article/2eed59c08fdd45b896bddf048a659297
Autor:
Lale Kostakoglu, Federico Dalmasso, Paola Berchialla, Larry A. Pierce, Umberto Vitolo, Maurizio Martelli, Laurie H. Sehn, Marek Trněný, Tina G. Nielsen, Christopher R. Bolen, Deniz Sahin, Calvin Lee, Tarec Christoffer El‐Galaly, Federico Mattiello, Paul E. Kinahan, Stephane Chauvie
Publikováno v:
eJHaem, Vol 3, Iss 2, Pp 406-414 (2022)
Abstract Image texture analysis (radiomics) uses radiographic images to quantify characteristics that may identify tumour heterogeneity and associated patient outcomes. Using fluoro‐deoxy‐glucose positron emission tomography/computed tomography (
Externí odkaz:
https://doaj.org/article/b8bbe56c53944bd0a888cd8d151c81e5
Autor:
Martin Štach, Robert Pytlík, Kristýna Šmilauerová, Jana Rychlá, Martin Mucha, Jan Musil, Abhishek Koladiya, Matěj Nemec, Martina Petráčková, Iva Kaštánková, Pavla Pecherková, Lucie Šrámková, Kamila Polgárová, Marek Trněný, Petr Lesný, Jan Vydra, Pavel Otáhal
Publikováno v:
Pathology and Oncology Research, Vol 29 (2023)
Tisagenlecleucel (tisa-cel) is a CD19-specific CAR-T cell product approved for the treatment of relapsed/refractory (r/r) DLBCL or B-ALL. We have followed a group of patients diagnosed with childhood B-ALL (n = 5), adult B-ALL (n = 2), and DLBCL (n =
Externí odkaz:
https://doaj.org/article/1d9dc7c6b478480589b2506dafb816b3
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Cutaneous T-cell lymphomas (CTCL) represent rare non-Hodgkin lymphomas (NHL) with an incidence less than 1 per 100,000 inhabitants. The most common type of CTCL is mycosis fungoides (MF), which represents approximately 60% of all CTCL, followed by S
Externí odkaz:
https://doaj.org/article/ebb9d617038443f2a027b642d45f5cfc
Autor:
Michael Herold, Eva Hoster, Ann Janssens, Helen McCarthy, Alessandra Tedeschi, Chris Pocock, Andras Rosta, Marek Trněný, Tina G. Nielsen, Andrea Knapp, Wolfgang Hiddemann, Robert Marcus
Publikováno v:
HemaSphere, Vol 6, Iss 3, p e699 (2022)
The aim of this study was to explore the efficacy and safety of obinutuzumab (G)- versus rituximab (R)-chemotherapy in a subgroup of patients with previously untreated marginal zone lymphoma (MZL) in the phase III GALLIUM trial (NCT01332968). Patient
Externí odkaz:
https://doaj.org/article/2ac4e9cc093c4c8a8597a1c6f7eef7fe
Autor:
Vít Procházka, David Belada, Andrea Janíková, Kateřina Benešová, Heidi Mociková, Juraj Ďuraš, Jan Pirnos, Kateřina Kopečková, Vít Campr, Tomáš Fürst, Robert Pytlík, Alice Sýkorová, Jozef Michalka, Jitka Dlouhá, Tomáš Papajík, Marek Trněný
Publikováno v:
eJHaem, Vol 1, Iss 1, Pp 170-180 (2020)
Abstract Twenty percent of patients with high‐tumor‐burden (HTB) follicular lymphoma (FL) develop progression/relapse of disease (POD) within 24 months of frontline immunochemotherapy. Unfortunately, about 50% of these patients die within 5 years
Externí odkaz:
https://doaj.org/article/36f7a329607444baa20175f7789312f1
Autor:
Laurie H. Sehn, Maurizio Martelli, Marek Trněný, Wenxin Liu, Christopher R. Bolen, Andrea Knapp, Deniz Sahin, Gila Sellam, Umberto Vitolo
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-9 (2020)
Abstract Background Rituximab (R) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) is the current standard therapy for diffuse large B cell lymphoma (DLBCL). Obinutuzumab (G), a glycoengineered, type II anti-CD20 monoclonal anti
Externí odkaz:
https://doaj.org/article/071cf3f888fc49b89a4d025320426315
Autor:
Lale Kostakoglu, Federico Mattiello, Maurizio Martelli, Laurie H. Sehn, David Belada, Chiara Ghiggi, Neil Chua, Eva González-Barca, Xiaonan Hong, Antonio Pinto, Yuankai Shi, Yoichi Tatsumi, Christopher Bolen, Andrea Knapp, Gila Sellam, Tina Nielsen, Deniz Sahin, Umberto Vitolo, Marek Trněný
Publikováno v:
Haematologica, Vol 107, Iss 7 (2021)
This retrospective analysis of the phase III GOYA study investigated the prognostic value of baseline metabolic tumor volume parameters and maximum standardized uptake values for overall and progression-free survival (PFS) in treatment-naïve diffuse
Externí odkaz:
https://doaj.org/article/62cf82718d3a48d2a7f753b32e69d5d4